154 related articles for article (PubMed ID: 33625041)
1. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication.
Shah S; Hill A
Curr Opin HIV AIDS; 2021 Mar; 16(2):106-114. PubMed ID: 33625041
[TBL] [Abstract][Full Text] [Related]
2. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.
Shah S; Hill A
Curr Opin Infect Dis; 2021 Feb; 34(1):16-24. PubMed ID: 33278177
[TBL] [Abstract][Full Text] [Related]
3. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
4. Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model.
Perna A; Carleo MA; Mascolo S; Guida A; Contieri M; Sellitto C; Hay E; De Blasiis P; Lucariello A; Guerra G; Baldi A; De Luca A; Maggi P; Esposito V
AIDS; 2023 Mar; 37(4):561-570. PubMed ID: 36504092
[TBL] [Abstract][Full Text] [Related]
5. Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV.
Lake JE; Trevillyan J
Curr Opin HIV AIDS; 2021 May; 16(3):148-151. PubMed ID: 33797433
[TBL] [Abstract][Full Text] [Related]
6. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
7. Weight gain and integrase inhibitors.
Eckard AR; McComsey GA
Curr Opin Infect Dis; 2020 Feb; 33(1):10-19. PubMed ID: 31789693
[TBL] [Abstract][Full Text] [Related]
8. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Consequences of Antiretroviral Therapy.
Diggins CE; Russo SC; Lo J
Curr HIV/AIDS Rep; 2022 Apr; 19(2):141-153. PubMed ID: 35299263
[TBL] [Abstract][Full Text] [Related]
10. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
11. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
12. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
13. Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States.
Emond B; Rossi C; Rogers R; Lefebvre P; Lafeuille MH; Donga P
J Health Econ Outcomes Res; 2022; 9(1):39-49. PubMed ID: 35233432
[No Abstract] [Full Text] [Related]
14. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan.
Kanda N; Okamoto K; Okumura H; Mieno M; Sakashita K; Sasahara T; Hatakeyama S
HIV Med; 2021 Jul; 22(6):457-466. PubMed ID: 33720508
[TBL] [Abstract][Full Text] [Related]
15. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
[TBL] [Abstract][Full Text] [Related]
16. Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?
Shah S; Hindley L; Hill A
Drugs; 2021 Feb; 81(3):299-315. PubMed ID: 33400239
[TBL] [Abstract][Full Text] [Related]
17. Metabolic-Related Outcomes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Adults With Human Immunodeficiency Virus (HIV): A Multicenter Prospective Cohort Study.
Martínez-Sanz J; Serrano-Villar S; Muriel A; García Fraile LJ; Orviz E; Mena de Cea Á; Campins AA; Moreno S
Clin Infect Dis; 2023 Feb; 76(3):e652-e660. PubMed ID: 35903910
[TBL] [Abstract][Full Text] [Related]
18. Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV.
Plum PE; Maes N; Sauvage AS; Frippiat F; Meuris C; Uurlings F; Lecomte M; Léonard P; Paquot N; Fombellida K; Vaira D; Moutschen M; Darcis G
BMC Infect Dis; 2021 Sep; 21(1):910. PubMed ID: 34488664
[TBL] [Abstract][Full Text] [Related]
19. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
[TBL] [Abstract][Full Text] [Related]
20. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
